Romain Altwegg
机构：Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, Hôpital Saint Eloi · ORCID：0000-0003-4618-7942
发表论文 254 篇 · 总被引 4253 次 · h-index 34
代表论文
- Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study (2024 · The Lancet · 被引 114)
- Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies (2024 · The Lancet · 被引 104)
- Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial (2024 · Gut · 被引 25)
- Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study (2025 · Alimentary Pharmacology & Therapeutics · 被引 13)
- Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study (2025 · Alimentary Pharmacology & Therapeutics · 被引 13)
- Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis (2025 · Clinical Gastroenterology and Hepatology · 被引 12)